Recently stock market analysts have updated their consensus ratings on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/03/2016 – Alnylam Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 119 price target on the stock.

05/03/2016 – Alnylam Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 107 price target on the stock.

04/05/2016 – Chardan Capital began new coverage on Alnylam Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 93 price target on the stock.

03/11/2016 – Alnylam Pharmaceuticals, Inc. was upgraded to “overweight” by analysts at JP Morgan. They now have a USD 81 price target on the stock.

02/12/2016 – Alnylam Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 102 price target on the stock.

01/28/2016 – FBR Capital Markets began new coverage on Alnylam Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 180 price target on the stock.

01/20/2016 – Credit Suisse began new coverage on Alnylam Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 154 price target on the stock.

12/07/2015 – Alnylam Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 150 price target on the stock.

11/26/2015 – Alnylam Pharmaceuticals, Inc. was downgraded to “hold” by analysts at S&P Capital IQ.

11/04/2015 – Alnylam Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 152 price target on the stock.

08/26/2015 – Alnylam Pharmaceuticals, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 144 price target on the stock.

06/24/2015 – Alnylam Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 155 price target on the stock.

06/24/2015 – Alnylam Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 160 price target on the stock.

05/08/2015 – Alnylam Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Zacks.

03/17/2015 – Janney Montgomery Scott began new coverage on Alnylam Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 139 price target on the stock.

Alnylam Pharmaceuticals, Inc. has a 50 day moving average of 65.48 and a 200 day moving average of 77.37. The stock’s market capitalization is 4.73B, it has a 52-week low of 51.51 and a 52-week high of 140.00.

The share price of the company (NASDAQ:ALNY) was down -5.41%, with a high of 59.15during the day and the volume of Alnylam Pharmaceuticals, Inc. shares traded was 1323388.

View other investors thoughts on Alnylam Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.